Incyte is set to report second-quarter financial results on July 28, 2026, as investors focus on whether momentum in its core franchises can be sustained alongside expanding late-stage oncology and pipeline catalysts. The company’s growth outlook also hinges on progress across multiple 2026 readouts, which management last updated in April.
Key takeaways
- Stock move: Incyte shares closed at $117.67 on July 27, 2026, up 0.84%.
- Upcoming catalyst: Second-quarter results are scheduled for July 28, 2026.
- Core drivers: Sales trends across Jakafi and Opzelura, plus faster-growing newer products such as Zynyz, are expected to remain central.
- Milestones in 2026: Multiple Phase 2 and Phase 3 topline events are expected across chronic GVHD, hidradenitis suppurativa, prurigo nodularis, and other programs.
- Financial targets: Full-year 2026 net sales guidance calls for $4.77 billion to $4.94 billion.
What investors will be watching ahead of the earnings report
Heading into the quarterly update, analysts and shareholders are likely to zero in on two areas: how the company’s established drugs are performing and whether commercial traction from newer launches remains strong. Incyte’s therapeutic focus spans hematology, oncology, inflammation, and autoimmunity, and the product mix continues to evolve with several oncology assets contributing meaningfully in the first half of 2026.
From a portfolio standpoint, the run-rate behind Jakafi and Opzelura remains especially important because it anchors both near-term revenue expectations and the company’s ability to fund ongoing clinical development.
First-quarter 2026 performance shows broad-based growth
In the first quarter of 2026, Incyte reported net income of $303.33 million, or $1.47 per share, compared with $158.20 million, or $0.80 per share, a year earlier. Total revenue rose to $1.27 billion from $1.05 billion in the prior-year period.
Key product sales continued to expand across multiple categories. Jakafi revenue increased 7% to $757.76 million, improving from $709.41 million. Opzelura sales climbed 20% to $143.02 million from $118.71 million, reflecting demand across its atopic dermatitis and vitiligo indications. Iclusig grew 20% to $35.46 million from $29.54 million.
Several newer oncology and late-stage contributors also recorded faster growth. Pemazyre revenue rose 22% to $22.54 million from $18.44 million, while Minjuvi/Monjuvi increased 67% to $49.23 million from $29.55 million. Niktimvo revenue improved sharply to $55.09 million, up from $13.61 million, and Zynyz—used for squamous cell carcinoma of the anal canal—jumped to $41.39 million from $3.01 million.
In addition, the company ended the quarter with $4 billion in cash, cash equivalents, and marketable securities as of March 31, 2026.
Near-term 2026 milestones add timing risk—and upside
Beyond sales, Incyte’s schedule of clinical data points shapes market expectations for the remainder of the year. In April 2026, the company updated multiple timelines for topline data across immunology, dermatology, hematology, and oncology.
- Chronic GVHD: Topline data from a Phase 2 trial evaluating Axatilimab plus ruxolitinib in newly diagnosed chronic GVHD is anticipated in the second half of 2026.
- Hidradenitis suppurativa: Topline results from Phase 3 studies (TRuE-HS1 and TRuE-HS2) for ruxolitinib cream in mild to moderate hidradenitis suppurativa are expected in the fourth quarter of 2026.
- Prurigo nodularis: Phase 3 readouts (STOP-PN1 and STOP-PN2) for povorcitinib in moderate-to-severe prurigo nodularis are also anticipated in the fourth quarter of 2026.
- Asthma: Phase 2 proof-of-concept data for povorcitinib in asthma are expected in the second half of 2026.
- Early-stage MPN biology: Phase 1 data for INCB160058 in myeloproliferative neoplasms with a JAK2V617F mutation are expected in the second half of 2026.
- Metastatic pancreatic cancer: Additional Phase 1 data for INCB161734 combined with standard-of-care chemotherapy as first-line treatment in metastatic pancreatic ductal adenocarcinoma are anticipated in the second half of 2026.
- Solid tumors: Additional Phase 1 information for INCA33890 combined with bevacizumab and/or chemotherapy in solid tumors is expected in the second half of 2026.
For investors, the breadth of these milestones matters because clinical timing can influence expectations for future growth and potential expansion of the company’s platform beyond its current commercial base. Any delays or weaker-than-expected outcomes could shift sentiment, while positive data could broaden the path for longer-term revenue durability.
2026 guidance frames expectations for commercial delivery
Incyte’s full-year 2026 guidance calls for total net sales of $4.77 billion to $4.94 billion. Jakafi net sales are expected to be $3.22 billion to $3.27 billion, while Opzelura is guided at $750 million to $790 million. The company also expects hematology and oncology portfolio sales to range between $800 million and $880 million.
With the second-quarter report approaching, shareholders are likely to compare realized revenue trends against this range and assess whether the accelerating contributions from newer products can offset any volatility from pricing, mix, or competitive dynamics.
Market reaction and what to watch next
Incyte shares have traded between $69.69 and $119.60 over the last year, and they closed at $117.67 on July 27, 2026, up 0.84%. Into the July 28 results, the key focus will be reported revenue growth, product-level trends across Jakafi and Opzelura, and whether the company maintains strong momentum in faster-growing franchises such as Zynyz.
Investors will also watch management commentary for updates on the timing and readiness of major 2026 data catalysts, as well as any incremental guidance refinement for the full year following the second-quarter readout.
